Table 3.
Clinical characteristics of kidney transplant recipients according to their immunosuppression regimen at the time of SARS-CoV-2 infection diagnosis.
| CNI | CNI free | p | |
|---|---|---|---|
| n = 106 | n = 59 | ||
| Age (years) | |||
| Mean (SD) | 48.2 | 49.1 | .694 |
| Median (IQR) | 45 | 49.1 | |
| Range | 52 | 73.4 | |
| BMI (kg/cm2) | |||
| Mean (SD) | 25.33 | 25.56 | .71 |
| Median (IQR) | 25.18 | 25.47 | |
| Range | 25.26 | 17.61 | |
| Months since transplant | |||
| Mean (SD) | 7.5 | 5.8 | .082 |
| Median (IQR) | 5.2 | 4.3 | |
| Range | 34.2 | 19.1 | |
| Age > 60 | 25 (23.6) | 15 (25.4) | .109 |
| Males | 64 (60.4) | 35 (59.3) | .004 |
| Less than 6 months | 12 (11.3) | 2 (3.4) | .019 |
| Hypertension | 76 (71.7) | 38 (64.49) | .271 |
| Diabetes | 30 (28.3) | 14 (23.7) | .525 |
| BMI > 30 kg/m2 | 10 (9.4) | 4 (6.8) | .71 |
| Steroids | 85 (80.2) | 45 (76.3) | .556 |
| Presenting symptoms | |||
| Fever | 59 (55.7) | 39 (66.1) | .15 |
| Nasal congestion | 9 (8.5) | 10 (16.9) | .092 |
| Cough | 56 (52.8) | 35 (59.3) | .355 |
| Odynophagia | 24 (22.6) | 13 (22) | .973 |
| Dyspnea | 44 (41.5) | 20 (33.9) | .378 |
| Myalgia | 52 (49.1) | 25 (42.4) | .466 |
| Diarrhea | 37 (34.9) | 14 (23.7) | .156 |
| Fatigue | 56 (52.8) | 19 (32.2) | .015 |
| Anosmia/dysgeusia | 10 (9.4) | 8 (13.6) | .396 |
| Clinical findings | |||
| Hypoxemia | 42 (39.6) | 21 (35.6) | .61 |
| Pulmonary infiltrates | 52 (49.1) | 35 (59.3) | .207 |
| Hospitalization | 54 (50.9) | 28 (47.5) | .668 |
| Mechanical ventilation | 25 (23.6) | 11 (18.6) | .837 |
| Hemodialysis | 10 (9.4) | 5 (8.5) | .462 |
| Treatment | |||
| Hydroxychloroquine | 3 (2.8) | 0 | .99 |
| Lopinavir/ritonavir | 1 (0.9) | 0 | 1 |
| Ivermectin | 21 (19.8) | 10 (16.9) | .652 |
| Dexamethasone | 37 (34.9) | 16 (27.1) | .306 |
| Antibiotics | 43 (40.6) | 24 (40.7) | .995 |
| Death | 23 (21.7) | 5 (8.5) | .036 |